We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Stool-Based DNA Testing Leads to Timely Colonoscopy

By LabMedica International staff writers
Posted on 15 Oct 2025

Colorectal cancer (CRC) remains a leading cause of cancer deaths in the US, yet many patients delay colonoscopy due to hesitancy and long wait times. More...

Long follow-up intervals after stool-based testing could further exacerbate health disparities in rural patients who already face significant barriers to health care. Now, a new observational study has shown that stool-based DNA testing can provide timely follow-up for both rural and urban patients and thus help increase equitable CRC screening.

The observational case–control analysis by researchers from the University of North Dakota (Grand Forks, ND, USA) included 1316 patients 18 years or older who had a positive DNA-based stool test and subsequently underwent diagnostic colonoscopy between January 2018 and December 2023. Participants were categorized as rural or nonrural using Rural-Urban Commuting Area codes, and the primary outcome was days from a positive stool test to diagnostic colonoscopy.

Of the 1,316 patients included, 668 (50.8% were classified as rural; the median time to diagnostic colonoscopy was similar between groups — 35 days for rural patients versus 37 days for nonrural patients (P=.6). Rural patients were significantly more likely to have their colonoscopy performed at an external facility (25% vs 3.1%; P<.001), despite comparable timeliness. In their research published in The American Surgeon, the authors note limitations, including reliance on recorded data and that the analysis focused only on patients who completed both stool testing and colonoscopy.

The investigators concluded that the findings support stool-based DNA testing as a tool to increase screening access and deliver timely diagnostic follow-up across geographic settings. At the study institution, the results informed plans to use stool-based testing for all low-risk patients, helping to stratify who needs diagnostic colonoscopy versus ongoing noninvasive monitoring. Broader adoption of stool-based testing could reduce missed diagnoses, shorten time to treatment, and help close rural–urban screening gaps.

“With all patients receiving colonoscopy in our system, patients had an average wait time of 1 year from initial contact to colonoscopy,” wrote the researchers. “It is also more accessible for many patients and helps stratify low-risk individuals, identifying those who require diagnostic colonoscopy vs. those who can be adequately monitored with stool-based testing alone.”


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Noul’s AI-based cervical cancer diagnostic solution, miLab CER (Photo courtesy of Noul)

AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America

Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.